Yifeng Hou

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 9

Top Topics

Peritoneal Dialysis

Breast Cancer Cells

Ejection Fraction

Top Venues

Cell death & disease

This page only lists publications with an associated author ORCID identifier.

Publications

Baojin Xu, Hefen Sun, Simeng Liu, Li Liao, Xiaoqing Song, Yi Wu, Yifeng Hou, Wei Jin
IFI35 limits antitumor immunity in triple-negative breast cancer via CCL2 secretion. Oncogene (2024)
Baojin Xu, Hefen Sun, Simeng Liu, Li Liao, Xiaoqing Song, Yi Wu, Yifeng Hou, Wei Jin
IFI35 limits antitumor immunity in triple-negative breast cancer via CCL2 secretion. Oncogene 43 (10) (2024)
Baojin Xu, Hefen Sun, Simeng Liu, Li Liao, Xiaoqing Song, Yi Wu, Yifeng Hou, Wei Jin
IFI35 limits antitumor immunity in triple-negative breast cancer via CCL2 secretion. Oncogene 43 (10) (2024)
Baojin Xu, Hefen Sun, Simeng Liu, Li Liao, Xiaoqing Song, Yi Wu, Yifeng Hou, Wei Jin
IFI35 limits antitumor immunity in triple-negative breast cancer via CCL2 secretion. Oncogene 43 (10) (2024)
Baojin Xu, Hefen Sun, Simeng Liu, Li Liao, Xiaoqing Song, Yi Wu, Yifeng Hou, Wei Jin
IFI35 limits antitumor immunity in triple-negative breast cancer via CCL2 secretion. Oncogene 43 (10) (2024)
Baojin Xu, Hefen Sun, Simeng Liu, Li Liao, Xiaoqing Song, Yi Wu, Yifeng Hou, Wei Jin
IFI35 limits antitumor immunity in triple-negative breast cancer via CCL2 secretion. Oncogene 43 (10) (2024)
Baojin Xu, Hefen Sun, Simeng Liu, Li Liao, Xiaoqing Song, Yi Wu, Yifeng Hou, Wei Jin
IFI35 limits antitumor immunity in triple-negative breast cancer via CCL2 secretion. Oncogene 43 (10) (2024)
Yuanyuan Zhao, Hefen Sun, Xuan Li, Qiqi Liu, Yang Liu, Yifeng Hou, Wei Jin
DGKZ promotes TGFβ signaling pathway and metastasis in triple-negative breast cancer by suppressing lipid raft-dependent endocytosis of TGFβR2. Cell death & disease 13 (2) (2022)
Yang Zhao, Hefen Sun, Yuanyuan Zhao, Qiqi Liu, Yang Liu, Yifeng Hou, Wei Jin
NSrp70 suppresses metastasis in triple-negative breast cancer by modulating Numb/TβR1/EMT axis. Oncogene 41 (25) (2022)